Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Medtide (泰德医药) IPO: Aggressive Valuation

Medtide (泰德医药) IPO Trading Update

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Medtide, a Chinese headquartered CDMO company, is seeking to raise at least USD 100m via a Hong Kong listing. The deal sponsors are MS and CITIC.</li>
<li>In this note, we take a quick look at the company’s fundamentals.</li>
<li>We highlighted its corporate governance risk despite its decent financials as compared to larger players.</li>
</ul>


Medtide, a Chinese headquartered CDMO company, is seeking to raise at least USD 100m via a Hong Kong listing. The deal sponsors are MS and CITIC.
In this note, we take a quick look at the company’s fundamentals.
We highlighted its corporate governance risk despite its decent financials as compared to larger players.


Guizhou Xinbang Pharmaceutical Co,Ltd. (002390 CH)

Medtide (泰德医药) Pre-IPO: Mind the CG Risk